Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

LESSONS LEARNED: A biweekly TAS‐102 plus BEV schedule in patients with heavily pretreated mCRC showed equivalent efficacy with less toxicity compared with the current schedule of TAS‐102 plus BEV combination. Biweekly TAS‐102 plus BEV combination could reduce unnecessary dose reduction of TAS‐102, m...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Satake, Hironaga, Kato, Takeshi, Oba, Koji, Kotaka, Masahito, Kagawa, Yoshinori, Yasui, Hisateru, Nakamura, Masato, Watanabe, Takanori, Matsumoto, Toshihiko, Kii, Takayuki, Terazawa, Tetsuji, Makiyama, Akitaka, Takano, Nao, Yokota, Mitsuru, Okita, Yoshihiro, Matoba, Koreatsu, Hasegawa, Hiroko, Tsuji, Akihito, Komatsu, Yoshito, Yoshino, Takayuki, Yamazaki, Kentaro, Mishima, Hideyuki, Oki, Eiji, Nagata, Naoki, Sakamoto, Junichi
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2020
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8108052/
https://ncbi.nlm.nih.gov/pubmed/32666647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0643
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi